NeoGenomics Valuation
| NEO Stock | USD 17.74 0.56 3.26% |
At this time, the firm appears to be fairly valued. NeoGenomics secures a last-minute Real Value of $17.13 per share. The latest price of the firm is $17.74. Our model forecasts the value of NeoGenomics from analyzing the firm fundamentals such as Profit Margin of (0.12) %, current valuation of 2.39 B, and Return On Equity of -0.0838 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NeoGenomics' valuation include:
Price Book 2.3928 | Enterprise Value 2.4 B | Enterprise Value Ebitda (27.92) | Price Sales 3.4237 | Forward PE 222.2222 |
Fairly Valued
Today
Please note that NeoGenomics' price fluctuation is not too volatile at this time. Calculation of the real value of NeoGenomics is based on 3 months time horizon. Increasing NeoGenomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeoGenomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeoGenomics Stock. However, NeoGenomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.74 | Real 17.13 | Target 20.36 | Hype 17.74 | Naive 17.15 |
The intrinsic value of NeoGenomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeoGenomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeoGenomics helps investors to forecast how NeoGenomics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeoGenomics more accurately as focusing exclusively on NeoGenomics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NeoGenomics' intrinsic value based on its ongoing forecasts of NeoGenomics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NeoGenomics' closest peers.
NeoGenomics Cash |
|
NeoGenomics Valuation Trend
Knowing NeoGenomics' actual value is paramount for traders when making sound investment determinations. Using both NeoGenomics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
NeoGenomics Total Value Analysis
NeoGenomics is now forecasted to have company total value of 2.39 B with market capitalization of 2.21 B, debt of 611.68 M, and cash on hands of 465.95 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the NeoGenomics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.39 B | 2.21 B | 611.68 M | 465.95 M |
NeoGenomics Investor Information
About 100.0% of the company shares are owned by institutional investors. The book value of NeoGenomics was now reported as 7.09. The company has Price/Earnings (P/E) ratio of 272.37. NeoGenomics recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 16th of April 2003. Based on the key indicators related to NeoGenomics' liquidity, profitability, solvency, and operating efficiency, NeoGenomics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.NeoGenomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeoGenomics has an asset utilization ratio of 35.19 percent. This suggests that the Company is making $0.35 for each dollar of assets. An increasing asset utilization means that NeoGenomics is more efficient with each dollar of assets it utilizes for everyday operations.NeoGenomics Ownership Allocation
NeoGenomics maintains a total of 128.36 Million outstanding shares. The majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company. Also note that almost one million one hundred fifty-five thousand two hundred fourty-nine invesors are currently shorting NeoGenomics expressing very little confidence in its future performance.NeoGenomics Profitability Analysis
The company reported the last year's revenue of 591.64 M. Reported Net Loss for the year was (87.97 M) with profit before taxes, overhead, and interest of 187.9 M.About NeoGenomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NeoGenomics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NeoGenomics based exclusively on its fundamental and basic technical indicators. By analyzing NeoGenomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NeoGenomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeoGenomics. We calculate exposure to NeoGenomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeoGenomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 244.6 M | 256.8 M | |
| Pretax Profit Margin | (0.16) | (0.17) | |
| Operating Profit Margin | (0.18) | (0.19) | |
| Net Loss | (0.15) | (0.16) | |
| Gross Profit Margin | 0.41 | 0.28 |
NeoGenomics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 125.5 M | |
| Quarterly Earnings Growth Y O Y | 1.306 | |
| Forward Price Earnings | 222.2222 |
NeoGenomics Current Valuation Indicators
NeoGenomics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final NeoGenomics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NeoGenomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NeoGenomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NeoGenomics' worth.When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.